Coexpression of survivin and TERT in soft-tissue sarcoma [7]

Lancet

Volumn 360, Issue 9336, 2002, Pages 877-

  Daidone, Maria Grazia ^a   Della Porta, Chiara ^a   Pilotti, Silvana ^a   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; SURVIVIN; TELOMERASE;

ACCURACY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONSERVATIVE TREATMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MASTECTOMY; MESODERM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA;

EID: 0037077869     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09984-1     Document Type: Letter

References (5)

1. Würl P., Kappler M., Meye A., et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet. 359:2002;943-945.
2. Daidone M.G., Abolafio G., Pilotti S., Zaffaroni N. Relationship between survivin expression and clinical progression in axillary lymph node-negative breast cancer (N-BC) patients. Proc AACR. 43:2002;4127.
3. Villa R., Della Porta C., Folini M., Daidone M.G., Zaffaroni N. Regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J Invest Dermatol. 116:2001;867-873.
4. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 7:2001;542-547.
5. Keith W.N., Evans T.R.J., Glasspool R.M. Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol. 195:2001;404-414.